IceCure’s ProSense System Gains Traction at EUSOBI 2026

The 12-month clinical results highlighted at the EUSOBI 2026 event demonstrated a 97.5% objective response rate in 40 patients treated with a combination of cryoablation and endocrine therapy. For patients treated with cryoablation alone, the response rate reached 91.7% among 24 participants. These findings were supported by research posters from centers in Romania and Italy, focusing on the efficacy of percutaneous procedures and the use of contrast-enhanced mammography to gauge histological response.

Beyond data reporting, the company hosted two workshops that drew nearly 70 participants each, emphasizing the shift toward de-escalated care in breast cancer treatment. Key sessions featured experts such as Dr. Lucía Graña-López and Dr. Francesca Pugliese, who explored the practical application of image-guided interventions. Eyal Shamir, CEO of IceCure Medical, noted that the high level of physician engagement at the meeting signals growing momentum for the company’s minimally invasive approach as an alternative to traditional surgery.